Avastin Warning

A statement issued on February 14th, by the FDA, warns patients and health professionals that a counterfeit version of Avastin 400 mg may have filtered down to some medical practices in the United States. The counterfeit version does not contain the medicine’s active ingredient, bevcizumab, which is needed for AMD therapy. The FDA informs doctors that the counterfeit version has a Roche label, and batch numbers and expiration dates inconsistent with Genetech’s approved format.

SEE FULL STORY